HeartBeam Inc. (NASDAQ: BEAT) has announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia. This development addresses a critical gap in ambulatory cardiac monitoring, where current patch-based devices cannot detect ischemia over extended periods. The study marks a significant step toward commercializing the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year. It often progresses silently until a major cardiac event occurs, making early detection vital. Healthcare providers are seeking faster and more accessible ways to identify high-risk patients, and HeartBeam's technology aims to address this need by providing clinical-grade insights through a patch that can generate on-demand 12-lead ECGs.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could revolutionize how we monitor patients for coronary artery disease and ischemia.”
The pilot study will evaluate the patch's ability to detect inadequate blood flow and oxygen supply to tissue, which is a key indicator of coronary artery disease. If successful, the HeartBeam patch could offer a non-invasive, convenient solution for continuous monitoring, potentially reducing the need for more invasive diagnostic procedures and enabling earlier intervention.
HeartBeam's innovation comes at a time when the seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk factors become more common. The company's focus on developing a patch that can provide on-demand 12-lead ECG data represents a potential leap forward in ambulatory cardiac monitoring, offering patients and physicians a tool that combines the convenience of a patch with the diagnostic power of a full 12-lead ECG.
For more information about HeartBeam and its latest news, visit the company’s newsroom at https://nnw.fm/BEAT.
